BioVentrix® Names Carl Byrnes Chief Financial Officer
91 German Hospitals Now Eligible to Negotiate Full Coverage for Revivent Therapy.
BioVentrix, Inc. Announces German Reimbursement Designation
91 German Hospitals Now Eligible to Negotiate Full Coverage for Revivent Therapy.
BioVentrix® Announces First Patient Treated with Revivent System in RELIVE Trial at Saint Luke’s Mid America Heart Institute
Pivotal RELIVE Trial Is Evaluating the Safety and Efficacy of BioVentrix’s Revivent System in the Treatment of Patients Who Have Experienced Heart Failure
BioVentrix Appoints Mark H. Ravich as Independent Board Member
Seasoned Executive Brings Strategic Insight and Financial Expertise to Support Company’s Governance and Funding Initiatives.
BioVentrix Appoints William T. Abraham, MD and Rishi Puri, MD, PhD, FRACP to Board of Directors
Renowned cardiovascular experts bring decades of clinical, research, and leadership [...]
BioVentrix® Names Vinod H. Thourani, MD and Marat Fudim, MD, MHS as National Co-Principal Investigators for its RELIVE Trial
Renowned Physicians in the Field of Cardiology to Lead [...]
BioVentrix® Names Steven Chartier President and Co-Chief Executive Officer
Brings Extensive Leadership Experience to Senior Management TeamMansfield, MA – [...]
BioVentrix® Closes $48.5 Million Series A Financing
Financing led by Andera Partners including Cormorant Asset Management, Taglich [...]
New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC® Therapy
Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device [...]
BioVentrix Names Dr. Ori Ben-Yehuda as Chief Medical Officer
Brings Extensive Clinical Trial and Patient Care Experience to Senior [...]
